Citigate Dewe Rogerson Citigate Dewe Rogerson is the leading international consultancy specialising exclusively in financial and corporate communications across the UK, Europe, North America and Asia. Citigate has a dedicated Pharma & Biotech team with more than 60 years combined experience in the sector and a unique mix of skills: corporate and financial PR and investor relations, finance, journalism and academic science. The team provides sector expertise and forms an integrated part of Citigate Dewe Rogerson, benefiting from the company’s overall strength and from the cross-fertilisation of ideas across sectors. The Citigate Pharma & Biotech team has an established track record in working with biotechnology companies at all stages in development. As well as core skills in financial calendar work, transactions support, financial PR and media relations, the team has extensive experience in branding, design and new media consultancy. Recent clients include global top-five biotechs, listed companies in the UK and Europe, and numerous emerging businesses in the UK, France, Germany, the Netherlands, and Scandinavia. Citigate’s Pharma & Biotech team has been involved in major corporate transactions such as IPOs, other public and private fundraisings, and M&As. We have advised on a number of IPO transactions across Europe including; METabolic EXplorer (Euronext Paris - €52 million), Algeta (Oslo Stock Exchange - €30 million), Santhera Pharmaceuticals (SWX – CH88.5 million), ThromboGenics (Euronext Brussels - €35 million), Hutchison China MediTech (AIM - £40 million), Zentiva (LSE and PSE – US $211 million), Arpida (SWX - €63 million), Inion (LSE - £35 million), TopoTarget (CSE - €30 million), BioFusion (AIM - £8.2 million) and ExonHit (Alternext - 7.3 million). |
 |
College Hill College Hill Life Sciences provides a full service communications consultancy focused on science-based sectors. Within the life science field we have established a leadership position by working in partnership with our clients to deliver high quality communications that build corporate value and promote leading edge products, technologies and services). |
 |
GoingPublic Media AG Founded in 1998 GoingPublic Media AG is today one of the leading publishers of magazines on capital markets, corporate finance and technology trends. In addition to the monthly issued “GoingPublic Magazin” and its well known yearly special editions like “Corporate Finance & Private Equity Guide” or “Biotechnology” which are largely meant as reference books, the company publishes the likewise monthly “VentureCapital Magazin”. It stands as a hub for the private equity and venture capital industry in German speaking Europe and addresses investors and entrepreneurs who focus on trends in technology, corporate financing and venture capital/private equity. Since 2003, the monthly issued magazine Smart Investor addresses retail investors. The quarterly published “HV Magazin” focuses on organizational, technical und legal trends concerning the annual shareholder meeting and is directed to the responsibles of listed companies (CFOs, investor relations managers etc.). The publication “Unternehmeredition” addresses with already 5 issues in 2008 Small & Medium-Sized Entrepreneurs. “Die Stiftung”, which was acquired in May 2008, is the latest magazine in the publishing program. With 17.000 recipients in Germany, Austria and Switzerland “Die Stiftung” is the magazine with the highest coverage in the foundation system market within the German speaking area. Furthermore GoingPublic Media operates the corporate publishing division GoingPublic Services. About 10 magazines and newsletters are annually distributed on behalf of well-known venture capital companies and financial institutions. Since November 2006 GoingPublic Media is listed in the Open Market of Frankfurt Stock Exchange. All publications are published in German. Contact: |
 |
PharmaDeals Whether you require data for benchmarking, competition analysis or simply to find out what new intellectual properties are being licensed, PharmaDeals® gives you access to the latest deal making information in the pharmaceutical and biotech field. Intelligently indexed, the new PharmaDeals v2 database is the ultimate benchmarking tool. PharmaDeals is brought to you by PharmaVentures, Experts in Deals and Alliances. With PharmaDeals v2, you benefit from using this unique set of business tools that offers you a flexible and cost effective resource to assist you in your deal making activities:
Find out more about PharmaDeals: www.pharmadeals.net If you would like to request a demonstration of PharmaDeals v2, please contact Silvia Serra on +44 (0) 1865 784 195 or e-mail sales@pharmaventures.com. PharmaDeals® is a registered Trade Mark of PharmaVentures Ltd. |
 |
Venture Valuation Venture Valuation specializes in independent assessment and valuation of technology-driven companies in growth industries, such as the Life Sciences (Biotech, Pharma, Medtech), ICT, high-tech, Nanotech, Cleantech and Renewable energy. In addition to valuation products, Venture Valuation offers high-quality, focused information services. Through our focus and unique position, we strive to fulfill and surpass our customer needs and add value to the partnership. Clients include investors, companies and development agencies. |
 |
| SwissBiotech – One Nation – One Biotech Cluster SwissBiotech unites the various biotech regions of Switzerland: in a targeted manner, the alliance raises Switzerland's profile as an economic centre abroad and positions its biotech regions as innovative and entrepreneurial focal points of research and production. Its mission; to spread the message of Switzerland as one of the top biotech locations in the world. This will be achieved by presenting a comprehensive picture of biotechnology including research, education, economics, finance and industry. The base for success in Biotechnology is the critical mass of research institutes and rapid Tec transfer. The vicinity to industry and well-trained workforce is another key-driver for success in economy. Recently regions in Switzerland opened a series of ‘Biotech-Parks’ thus enabling to offer ideal geographical placement of companies seeking short distances and increased know-how transfer between universities and industry. State-of-the-art technological infrastructures, productive international human resources and a traditional well publicized quality of life. Six founding members: Swiss online life-science database available The national portal www.swissbiotech.org holds unique information relating to all questions on Biotechnology in Switzerland. SwissBiotech |
 |